for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Elsevier   (Total: 3043 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 4 5 6 7 8 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 3043 Journals sorted alphabetically
AASRI Procedia     Open Access   (Followers: 15)
Academic Pediatrics     Hybrid Journal   (Followers: 20, SJR: 1.402, h-index: 51)
Academic Radiology     Hybrid Journal   (Followers: 18, SJR: 1.008, h-index: 75)
Accident Analysis & Prevention     Partially Free   (Followers: 83, SJR: 1.109, h-index: 94)
Accounting Forum     Hybrid Journal   (Followers: 23, SJR: 0.612, h-index: 27)
Accounting, Organizations and Society     Hybrid Journal   (Followers: 27, SJR: 2.515, h-index: 90)
Achievements in the Life Sciences     Open Access   (Followers: 4)
Acta Anaesthesiologica Taiwanica     Open Access   (Followers: 5, SJR: 0.338, h-index: 19)
Acta Astronautica     Hybrid Journal   (Followers: 333, SJR: 0.726, h-index: 43)
Acta Automatica Sinica     Full-text available via subscription   (Followers: 3)
Acta Biomaterialia     Hybrid Journal   (Followers: 25, SJR: 2.02, h-index: 104)
Acta Colombiana de Cuidado Intensivo     Full-text available via subscription   (Followers: 1)
Acta de Investigación Psicológica     Open Access   (Followers: 2)
Acta Ecologica Sinica     Open Access   (Followers: 8, SJR: 0.172, h-index: 29)
Acta Haematologica Polonica     Free   (SJR: 0.123, h-index: 8)
Acta Histochemica     Hybrid Journal   (Followers: 3, SJR: 0.604, h-index: 38)
Acta Materialia     Hybrid Journal   (Followers: 225, SJR: 3.683, h-index: 202)
Acta Mathematica Scientia     Full-text available via subscription   (Followers: 5, SJR: 0.615, h-index: 21)
Acta Mechanica Solida Sinica     Full-text available via subscription   (Followers: 9, SJR: 0.442, h-index: 21)
Acta Oecologica     Hybrid Journal   (Followers: 9, SJR: 0.915, h-index: 53)
Acta Otorrinolaringologica (English Edition)     Full-text available via subscription   (Followers: 1)
Acta Otorrinolaringológica Española     Full-text available via subscription   (Followers: 3, SJR: 0.311, h-index: 16)
Acta Pharmaceutica Sinica B     Open Access   (Followers: 2)
Acta Poética     Open Access   (Followers: 4)
Acta Psychologica     Hybrid Journal   (Followers: 23, SJR: 1.365, h-index: 73)
Acta Sociológica     Open Access  
Acta Tropica     Hybrid Journal   (Followers: 6, SJR: 1.059, h-index: 77)
Acta Urológica Portuguesa     Open Access  
Actas Dermo-Sifiliograficas     Full-text available via subscription   (Followers: 4)
Actas Dermo-Sifiliográficas (English Edition)     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 4, SJR: 0.383, h-index: 19)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 2)
Actualites Pharmaceutiques     Full-text available via subscription   (Followers: 5, SJR: 0.141, h-index: 3)
Actualites Pharmaceutiques Hospitalieres     Full-text available via subscription   (Followers: 4, SJR: 0.112, h-index: 2)
Acupuncture and Related Therapies     Hybrid Journal   (Followers: 3)
Ad Hoc Networks     Hybrid Journal   (Followers: 11, SJR: 0.967, h-index: 57)
Addictive Behaviors     Hybrid Journal   (Followers: 15, SJR: 1.514, h-index: 92)
Addictive Behaviors Reports     Open Access   (Followers: 5)
Additive Manufacturing     Hybrid Journal   (Followers: 8, SJR: 1.039, h-index: 5)
Additives for Polymers     Full-text available via subscription   (Followers: 20)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 134, SJR: 5.2, h-index: 222)
Advanced Engineering Informatics     Hybrid Journal   (Followers: 11, SJR: 1.265, h-index: 53)
Advanced Powder Technology     Hybrid Journal   (Followers: 16, SJR: 0.739, h-index: 33)
Advances in Accounting     Hybrid Journal   (Followers: 9, SJR: 0.299, h-index: 15)
Advances in Agronomy     Full-text available via subscription   (Followers: 15, SJR: 2.071, h-index: 82)
Advances in Anesthesia     Full-text available via subscription   (Followers: 25, SJR: 0.169, h-index: 4)
Advances in Antiviral Drug Design     Full-text available via subscription   (Followers: 3)
Advances in Applied Mathematics     Full-text available via subscription   (Followers: 6, SJR: 1.054, h-index: 35)
Advances in Applied Mechanics     Full-text available via subscription   (Followers: 10, SJR: 0.801, h-index: 26)
Advances in Applied Microbiology     Full-text available via subscription   (Followers: 22, SJR: 1.286, h-index: 49)
Advances In Atomic, Molecular, and Optical Physics     Full-text available via subscription   (Followers: 16, SJR: 3.31, h-index: 42)
Advances in Biological Regulation     Hybrid Journal   (Followers: 4, SJR: 2.277, h-index: 43)
Advances in Botanical Research     Full-text available via subscription   (Followers: 3, SJR: 0.619, h-index: 48)
Advances in Cancer Research     Full-text available via subscription   (Followers: 25, SJR: 2.215, h-index: 78)
Advances in Carbohydrate Chemistry and Biochemistry     Full-text available via subscription   (Followers: 9, SJR: 0.9, h-index: 30)
Advances in Catalysis     Full-text available via subscription   (Followers: 5, SJR: 2.139, h-index: 42)
Advances in Cellular and Molecular Biology of Membranes and Organelles     Full-text available via subscription   (Followers: 12)
Advances in Chemical Engineering     Full-text available via subscription   (Followers: 24, SJR: 0.183, h-index: 23)
Advances in Child Development and Behavior     Full-text available via subscription   (Followers: 10, SJR: 0.665, h-index: 29)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 10, SJR: 1.268, h-index: 45)
Advances in Clinical Chemistry     Full-text available via subscription   (Followers: 28, SJR: 0.938, h-index: 33)
Advances in Colloid and Interface Science     Full-text available via subscription   (Followers: 18, SJR: 2.314, h-index: 130)
Advances in Computers     Full-text available via subscription   (Followers: 16, SJR: 0.223, h-index: 22)
Advances in Developmental Biology     Full-text available via subscription   (Followers: 11)
Advances in Digestive Medicine     Open Access   (Followers: 4)
Advances in DNA Sequence-Specific Agents     Full-text available via subscription   (Followers: 5)
Advances in Drug Research     Full-text available via subscription   (Followers: 22)
Advances in Ecological Research     Full-text available via subscription   (Followers: 42, SJR: 3.25, h-index: 43)
Advances in Engineering Software     Hybrid Journal   (Followers: 25, SJR: 0.486, h-index: 10)
Advances in Experimental Biology     Full-text available via subscription   (Followers: 7)
Advances in Experimental Social Psychology     Full-text available via subscription   (Followers: 40, SJR: 5.465, h-index: 64)
Advances in Exploration Geophysics     Full-text available via subscription   (Followers: 3)
Advances in Fluorine Science     Full-text available via subscription   (Followers: 8)
Advances in Food and Nutrition Research     Full-text available via subscription   (Followers: 47, SJR: 0.674, h-index: 38)
Advances in Fuel Cells     Full-text available via subscription   (Followers: 15)
Advances in Genetics     Full-text available via subscription   (Followers: 15, SJR: 2.558, h-index: 54)
Advances in Genome Biology     Full-text available via subscription   (Followers: 11)
Advances in Geophysics     Full-text available via subscription   (Followers: 6, SJR: 2.325, h-index: 20)
Advances in Heat Transfer     Full-text available via subscription   (Followers: 21, SJR: 0.906, h-index: 24)
Advances in Heterocyclic Chemistry     Full-text available via subscription   (Followers: 8, SJR: 0.497, h-index: 31)
Advances in Human Factors/Ergonomics     Full-text available via subscription   (Followers: 26)
Advances in Imaging and Electron Physics     Full-text available via subscription   (Followers: 2, SJR: 0.396, h-index: 27)
Advances in Immunology     Full-text available via subscription   (Followers: 35, SJR: 4.152, h-index: 85)
Advances in Inorganic Chemistry     Full-text available via subscription   (Followers: 9, SJR: 1.132, h-index: 42)
Advances in Insect Physiology     Full-text available via subscription   (Followers: 3, SJR: 1.274, h-index: 27)
Advances in Integrative Medicine     Hybrid Journal   (Followers: 5)
Advances in Intl. Accounting     Full-text available via subscription   (Followers: 4)
Advances in Life Course Research     Hybrid Journal   (Followers: 8, SJR: 0.764, h-index: 15)
Advances in Lipobiology     Full-text available via subscription   (Followers: 2)
Advances in Magnetic and Optical Resonance     Full-text available via subscription   (Followers: 9)
Advances in Marine Biology     Full-text available via subscription   (Followers: 16, SJR: 1.645, h-index: 45)
Advances in Mathematics     Full-text available via subscription   (Followers: 10, SJR: 3.261, h-index: 65)
Advances in Medical Sciences     Hybrid Journal   (Followers: 6, SJR: 0.489, h-index: 25)
Advances in Medicinal Chemistry     Full-text available via subscription   (Followers: 5)
Advances in Microbial Physiology     Full-text available via subscription   (Followers: 4, SJR: 1.44, h-index: 51)
Advances in Molecular and Cell Biology     Full-text available via subscription   (Followers: 22)
Advances in Molecular and Cellular Endocrinology     Full-text available via subscription   (Followers: 10)
Advances in Molecular Toxicology     Full-text available via subscription   (Followers: 7, SJR: 0.324, h-index: 8)
Advances in Nanoporous Materials     Full-text available via subscription   (Followers: 4)
Advances in Oncobiology     Full-text available via subscription   (Followers: 3)
Advances in Organometallic Chemistry     Full-text available via subscription   (Followers: 15, SJR: 2.885, h-index: 45)
Advances in Parallel Computing     Full-text available via subscription   (Followers: 7, SJR: 0.148, h-index: 11)
Advances in Parasitology     Full-text available via subscription   (Followers: 7, SJR: 2.37, h-index: 73)
Advances in Pediatrics     Full-text available via subscription   (Followers: 24, SJR: 0.4, h-index: 28)
Advances in Pharmaceutical Sciences     Full-text available via subscription   (Followers: 13)
Advances in Pharmacology     Full-text available via subscription   (Followers: 15, SJR: 1.718, h-index: 58)
Advances in Physical Organic Chemistry     Full-text available via subscription   (Followers: 7, SJR: 0.384, h-index: 26)
Advances in Phytomedicine     Full-text available via subscription  
Advances in Planar Lipid Bilayers and Liposomes     Full-text available via subscription   (Followers: 3, SJR: 0.248, h-index: 11)
Advances in Plant Biochemistry and Molecular Biology     Full-text available via subscription   (Followers: 8)
Advances in Plant Pathology     Full-text available via subscription   (Followers: 5)
Advances in Porous Media     Full-text available via subscription   (Followers: 4)
Advances in Protein Chemistry     Full-text available via subscription   (Followers: 18)
Advances in Protein Chemistry and Structural Biology     Full-text available via subscription   (Followers: 19, SJR: 1.5, h-index: 62)
Advances in Psychology     Full-text available via subscription   (Followers: 60)
Advances in Quantum Chemistry     Full-text available via subscription   (Followers: 5, SJR: 0.478, h-index: 32)
Advances in Radiation Oncology     Open Access  
Advances in Small Animal Medicine and Surgery     Hybrid Journal   (Followers: 2, SJR: 0.1, h-index: 2)
Advances in Space Research     Full-text available via subscription   (Followers: 345, SJR: 0.606, h-index: 65)
Advances in Structural Biology     Full-text available via subscription   (Followers: 8)
Advances in Surgery     Full-text available via subscription   (Followers: 7, SJR: 0.823, h-index: 27)
Advances in the Study of Behavior     Full-text available via subscription   (Followers: 30, SJR: 1.321, h-index: 56)
Advances in Veterinary Medicine     Full-text available via subscription   (Followers: 16)
Advances in Veterinary Science and Comparative Medicine     Full-text available via subscription   (Followers: 13)
Advances in Virus Research     Full-text available via subscription   (Followers: 5, SJR: 1.878, h-index: 68)
Advances in Water Resources     Hybrid Journal   (Followers: 43, SJR: 2.408, h-index: 94)
Aeolian Research     Hybrid Journal   (Followers: 5, SJR: 0.973, h-index: 22)
Aerospace Science and Technology     Hybrid Journal   (Followers: 310, SJR: 0.816, h-index: 49)
AEU - Intl. J. of Electronics and Communications     Hybrid Journal   (Followers: 8, SJR: 0.318, h-index: 36)
African J. of Emergency Medicine     Open Access   (Followers: 5, SJR: 0.344, h-index: 6)
Ageing Research Reviews     Hybrid Journal   (Followers: 8, SJR: 3.289, h-index: 78)
Aggression and Violent Behavior     Hybrid Journal   (Followers: 408, SJR: 1.385, h-index: 72)
Agri Gene     Hybrid Journal  
Agricultural and Forest Meteorology     Hybrid Journal   (Followers: 15, SJR: 2.18, h-index: 116)
Agricultural Systems     Hybrid Journal   (Followers: 30, SJR: 1.275, h-index: 74)
Agricultural Water Management     Hybrid Journal   (Followers: 38, SJR: 1.546, h-index: 79)
Agriculture and Agricultural Science Procedia     Open Access  
Agriculture and Natural Resources     Open Access   (Followers: 1)
Agriculture, Ecosystems & Environment     Hybrid Journal   (Followers: 53, SJR: 1.879, h-index: 120)
Ain Shams Engineering J.     Open Access   (Followers: 5, SJR: 0.434, h-index: 14)
Air Medical J.     Hybrid Journal   (Followers: 5, SJR: 0.234, h-index: 18)
AKCE Intl. J. of Graphs and Combinatorics     Open Access   (SJR: 0.285, h-index: 3)
Alcohol     Hybrid Journal   (Followers: 9, SJR: 0.922, h-index: 66)
Alcoholism and Drug Addiction     Open Access   (Followers: 6)
Alergologia Polska : Polish J. of Allergology     Full-text available via subscription   (Followers: 1)
Alexandria Engineering J.     Open Access   (Followers: 1, SJR: 0.436, h-index: 12)
Alexandria J. of Medicine     Open Access  
Algal Research     Partially Free   (Followers: 8, SJR: 2.05, h-index: 20)
Alkaloids: Chemical and Biological Perspectives     Full-text available via subscription   (Followers: 3)
Allergologia et Immunopathologia     Full-text available via subscription   (Followers: 1, SJR: 0.46, h-index: 29)
Allergology Intl.     Open Access   (Followers: 4, SJR: 0.776, h-index: 35)
ALTER - European J. of Disability Research / Revue Européenne de Recherche sur le Handicap     Full-text available via subscription   (Followers: 7, SJR: 0.158, h-index: 9)
Alzheimer's & Dementia     Hybrid Journal   (Followers: 48, SJR: 4.289, h-index: 64)
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring     Open Access   (Followers: 5)
Alzheimer's & Dementia: Translational Research & Clinical Interventions     Open Access   (Followers: 3)
American Heart J.     Hybrid Journal   (Followers: 48, SJR: 3.157, h-index: 153)
American J. of Cardiology     Hybrid Journal   (Followers: 45, SJR: 2.063, h-index: 186)
American J. of Emergency Medicine     Hybrid Journal   (Followers: 38, SJR: 0.574, h-index: 65)
American J. of Geriatric Pharmacotherapy     Full-text available via subscription   (Followers: 6, SJR: 1.091, h-index: 45)
American J. of Geriatric Psychiatry     Hybrid Journal   (Followers: 16, SJR: 1.653, h-index: 93)
American J. of Human Genetics     Hybrid Journal   (Followers: 31, SJR: 8.769, h-index: 256)
American J. of Infection Control     Hybrid Journal   (Followers: 24, SJR: 1.259, h-index: 81)
American J. of Kidney Diseases     Hybrid Journal   (Followers: 33, SJR: 2.313, h-index: 172)
American J. of Medicine     Hybrid Journal   (Followers: 46, SJR: 2.023, h-index: 189)
American J. of Medicine Supplements     Full-text available via subscription   (Followers: 3)
American J. of Obstetrics and Gynecology     Hybrid Journal   (Followers: 187, SJR: 2.255, h-index: 171)
American J. of Ophthalmology     Hybrid Journal   (Followers: 54, SJR: 2.803, h-index: 148)
American J. of Ophthalmology Case Reports     Open Access   (Followers: 3)
American J. of Orthodontics and Dentofacial Orthopedics     Full-text available via subscription   (Followers: 6, SJR: 1.249, h-index: 88)
American J. of Otolaryngology     Hybrid Journal   (Followers: 23, SJR: 0.59, h-index: 45)
American J. of Pathology     Hybrid Journal   (Followers: 26, SJR: 2.653, h-index: 228)
American J. of Preventive Medicine     Hybrid Journal   (Followers: 21, SJR: 2.764, h-index: 154)
American J. of Surgery     Hybrid Journal   (Followers: 34, SJR: 1.286, h-index: 125)
American J. of the Medical Sciences     Hybrid Journal   (Followers: 12, SJR: 0.653, h-index: 70)
Ampersand : An Intl. J. of General and Applied Linguistics     Open Access   (Followers: 5)
Anaerobe     Hybrid Journal   (Followers: 4, SJR: 1.066, h-index: 51)
Anaesthesia & Intensive Care Medicine     Full-text available via subscription   (Followers: 55, SJR: 0.124, h-index: 9)
Anaesthesia Critical Care & Pain Medicine     Full-text available via subscription   (Followers: 9)
Anales de Cirugia Vascular     Full-text available via subscription  
Anales de Pediatría     Full-text available via subscription   (Followers: 2, SJR: 0.209, h-index: 27)
Anales de Pediatría (English Edition)     Full-text available via subscription  
Anales de Pediatría Continuada     Full-text available via subscription   (SJR: 0.104, h-index: 3)
Analytic Methods in Accident Research     Hybrid Journal   (Followers: 2, SJR: 2.577, h-index: 7)
Analytica Chimica Acta     Hybrid Journal   (Followers: 38, SJR: 1.548, h-index: 152)
Analytical Biochemistry     Hybrid Journal   (Followers: 164, SJR: 0.725, h-index: 154)
Analytical Chemistry Research     Open Access   (Followers: 8, SJR: 0.18, h-index: 2)
Analytical Spectroscopy Library     Full-text available via subscription   (Followers: 11)
Anesthésie & Réanimation     Full-text available via subscription   (Followers: 1)
Anesthesiology Clinics     Full-text available via subscription   (Followers: 22, SJR: 0.421, h-index: 40)
Angiología     Full-text available via subscription   (SJR: 0.124, h-index: 9)
Angiologia e Cirurgia Vascular     Open Access  
Animal Behaviour     Hybrid Journal   (Followers: 158, SJR: 1.907, h-index: 126)
Animal Feed Science and Technology     Hybrid Journal   (Followers: 5, SJR: 1.151, h-index: 83)
Animal Reproduction Science     Hybrid Journal   (Followers: 5, SJR: 0.711, h-index: 78)
Annales d'Endocrinologie     Full-text available via subscription   (Followers: 1, SJR: 0.394, h-index: 30)
Annales d'Urologie     Full-text available via subscription  
Annales de Cardiologie et d'Angéiologie     Full-text available via subscription   (SJR: 0.177, h-index: 13)
Annales de Chirurgie de la Main et du Membre Supérieur     Full-text available via subscription  
Annales de Chirurgie Plastique Esthétique     Full-text available via subscription   (Followers: 2, SJR: 0.354, h-index: 22)
Annales de Chirurgie Vasculaire     Full-text available via subscription   (Followers: 1)

        1 2 3 4 5 6 7 8 | Last   [Sort by number of followers]   [Restore default list]

Journal Cover Acta Haematologica Polonica
  [SJR: 0.123]   [H-I: 8]   [0 followers]  Follow
    
  Free journal Free journal
   ISSN (Print) 0001-5814
   Published by Elsevier Homepage  [3043 journals]
  • Diagnosing Beta Thalassemia trait in a developing country
    • Authors: Shan-e- Rauf; Ghassan Umair Shamshad; Fareeha Mushtaq; Saleem Ahmed Khan; Nadir Ali
      Pages: 18 - 22
      Abstract: Publication date: January–March 2017
      Source:Acta Haematologica Polonica, Volume 48, Issue 1
      Author(s): Shan-e- Rauf, Ghassan Umair Shamshad, Fareeha Mushtaq, Saleem Ahmed Khan, Nadir Ali
      Background Beta Thalassemia trait (BTT) is diagnosed by detecting hemoglobin A2 (HbA2) >3.8% on either High Performance Liquid Chromatography (HPLC) or cellulose acetate electrophoresis (CAE). HPLC is an accurate and reproducible but costly alternative to more conventional CAE which is labor intensive but easy to interpret and inexpensive. Objective To determine the sensitivity of CAE and HPLC keeping PCR as gold standard for the diagnosis of BTT. Study Design Cross sectional. Place and Duration of Study Armed Forces Institute of Pathology Rawalpindi. May 2014 to January 2015. Patient and Methods Fiveml EDTA anti-coagulated blood was collected from 100 PCR proven cases of BTT. HbA2 levels were measured by running samples directly on HPLC. But for CAE, first a hemolysate was prepared which was then applied to cellulose acetate membrane at an alkaline pH (7.9). After elution of HbA2 band in Tris EDTA borate buffer (pH of 8.9), HbA2 concentration was calculated by measuring its absorbance in a photometer at a wavelength of 416nm. Results Mean age of the patients was 28.8±8.1 year. The most common mutation was Fr 8–9 (35%) followed by IVS1-5 (25%) mutation. Mean HbA2 levels by CAE and HPLC were 4.97±0.42 and 5.54±0.59 respectively. All the patients had HbA2 >4% on both CAE and HPLC. None of our patients had false negative result either on CAE or HPLC. Conclusion CAE has comparable sensitivity with HPLC for detection of Beta Thalassemia Trait.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.01.001
       
  • Zakażenia wirusowe u dzieci po przeszczepieniu komórek krwiotwórczych:
           raport 2016 Polskiej Pediatrycznej Grupy ds. Zakażeń Polskiego
           Towarzystwa Onkologii i Hematologii Dziecięcej
    • Authors: Jan Styczyński; Krzysztof Czyżewski; Jowita Frączkiewicz; Małgorzata Salamonowicz; Olga Zając-Spychała; Agnieszka Zaucha-Prażmo; Jolanta Goździk; Patrycja Zalas-Więcek; Magdalena Dziedzic; Krzysztof Kałwak; Ewa Gorczyńska; Alicja Chybicka; Jacek Wachowiak; Jerzy Kowalczyk; Eugenia Gospodarek-Komkowska; Mariusz Wysocki
      Pages: 23 - 27
      Abstract: Publication date: January–March 2017
      Source:Acta Haematologica Polonica, Volume 48, Issue 1
      Author(s): Jan Styczyński, Krzysztof Czyżewski, Jowita Frączkiewicz, Małgorzata Salamonowicz, Olga Zając-Spychała, Agnieszka Zaucha-Prażmo, Jolanta Goździk, Patrycja Zalas-Więcek, Magdalena Dziedzic, Krzysztof Kałwak, Ewa Gorczyńska, Alicja Chybicka, Jacek Wachowiak, Jerzy Kowalczyk, Eugenia Gospodarek-Komkowska, Mariusz Wysocki
      Background Polish Pediatric Infectious Working Group of Polish Society of Pediatric Oncology and Hematology continues from 2012 the infections monitoring program in pediatric hematopoietic stem cell transplant (HSCT) and onco-hematology centers. Objective Epidemiological analysis of viral infections in children and adolescents undergoing HSCT in pediatric centers in 2012–2013 and 2014–2015. Methods Retrospective analysis of viral infections after 650 HSCT in children and adolescents. Results An increase in incidence in 2014–2015 was observed (60.6% vs 51.3%; OR=1.5; p=0.035) after allo-HSCT. Cumulative incidence after allo-HSCT (2012–2013 vs. 2014–2015) was: CMV – 28.0% vs. 29.2%, BKV – 18.5% vs. 22.8%, EBV – 15.5% vs. 24.3%, ADV – 9.5% vs. 5.2%, rotavirus – 9.1% vs. 5.6%, VZV – 2.6% vs. 1.1%, influenza – 0.9% vs. 3.4%, HHV6 – 0.9% vs. 1.5%, norovirus – 0% vs. 2.2%, RSV – 0% vs. 1.5%, parainfluenza – 0% vs. 0.7%, and MPV – 0% vs 0.4%. Infections after auto-HSCT occurred in 8 (10.5%) patients between 2012 and 2013 vs. 2 (2.6%) between 2014 and 2015. Cure rate after viral infections has increased (2012–2013 vs. 2014–2015) for: EBV – 90.7% vs. 100%, ADV – 93.8% vs. 100%, BKV – 94.2% vs. 96.8%, CMV – 94.6% vs. 98%, and remained 100% in infections with influenza, VZV, HHV6, rotavirus as well as in parainfluenza, RSV, and MPV. Decrease of deaths rate attributed to viral infections from 6.5% (2012–2013) to 0.7% (2014–2015) was observed after allo-HSCT. Conclusions We found epidemiological trends in viral infections after HSCT in children: increase in incidence after allo-HSCT (increase EBV, appearance of CARV) and decrease after auto-HSCT. Decrease of deaths attributed to viral infections was observed in the last period of time.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.11.006
       
  • Single Positive Commensal Blood Culture in hospital setting is associated
           with higher mortality after hematopoietic stem cell transplantation
    • Authors: Krzysztof Bogusz; Emilian Snarski; Patrycja Rusicka; Kazimierz Hałaburda; Tigran Torosian; Małgorzata Rokicka; Grzegorz Basak; Monika Paluszewska; Piotr Boguradzki; Grzegorz Charliński; Magdalena Tormanowska; Wiesław Wiktor Jędrzejczak
      Pages: 40 - 47
      Abstract: Publication date: January–March 2017
      Source:Acta Haematologica Polonica, Volume 48, Issue 1
      Author(s): Krzysztof Bogusz, Emilian Snarski, Patrycja Rusicka, Kazimierz Hałaburda, Tigran Torosian, Małgorzata Rokicka, Grzegorz Basak, Monika Paluszewska, Piotr Boguradzki, Grzegorz Charliński, Magdalena Tormanowska, Wiesław Wiktor Jędrzejczak
      Background Single positive staphylococcal blood culture in a hematopoietic stem cell transplantation (HSCT) recipient is generally regarded as contamination. Such a blood culture (BC) does not fill the criteria for Laboratory-Confirmed Bloodstream Infection (LCBI) and could be described as Single Positive Commensal Blood Culture. The aim of this retrospective cohort analysis was to determine the clinical significance of SPCBC in HSCT recipients. Methods 206 patients transplanted between 2007 and 2013 were followed until January 2015. Results The 100-day survival for patients without positive BC was 99.6% compared with 83.9% for LCBI and 82.8% for SPCBC (p =0.0036). The 5-year overall survival (5yOS) was 67.1% for patients without positive BC, 44.9% for LCBI, 34.0% for SPCBC (p <0.0001). The per-day risk of developing SPCBC was identical in autologous and allogenic transplantation. SPCBC remained a significant factor for reduced 5yOS after HSCT in the univariate analysis (HR 2.52, 1.26–5.02, p =0.0001) as well as in the multivariate analysis (HR 2.21, 1.26–3.87, p =0.006). SPCBC consisted solely of different Staphylococcus species with dominance of Staphylococcus epidermidis (64% of SPCBC). Conclusion To our knowledge this is the first report that specifically shows that short- and long-term survival after HSCT is significantly lower in patients who experience an episode of SPCBC with Staphylococcus spp. during HSCT hospitalization.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.11.004
       
  • Role of HLA match on results of hematopoietic stem cell transplantations
           from unrelated donors in children with acute leukemia and bone marrow
           failure syndromes
    • Authors: Jan Styczyński; Robert Dębski; Anna Krenska; Krzysztof Czyżewski; Natalia Bartoszewicz; Ewa Demidowicz; Ninela Irga-Jaworska; Elżbieta Drożyńska; Marcin Płonowski; Maryna Krawczuk-Rybak; Tomasz Ociepa; Tomasz Urasiński; Mariusz Wysocki
      Pages: 48 - 53
      Abstract: Publication date: January–March 2017
      Source:Acta Haematologica Polonica, Volume 48, Issue 1
      Author(s): Jan Styczyński, Robert Dębski, Anna Krenska, Krzysztof Czyżewski, Natalia Bartoszewicz, Ewa Demidowicz, Ninela Irga-Jaworska, Elżbieta Drożyńska, Marcin Płonowski, Maryna Krawczuk-Rybak, Tomasz Ociepa, Tomasz Urasiński, Mariusz Wysocki
      Background In case of the lack of matched family donors (MFD), hematopoietic stem cell transplantation (HSCT) from unrelated donor (UD) is an established procedure for many acquired and congenital disorders of the hematopoietic system, including malignancies and bone marrow failure (BMF) syndromes. Objective The analysis of the results of HSCT in patients with acute leukemia or BMF syndromes from UDs with respect to human leukocyte antigen (HLA) match. Patients and methods A total number of 97 of HSCT from UDs performed in single center between 2007 and 2015 in children and adolescents with acute lymphoblastic (ALL) or myeloblastic leukemia (AML) and BMF syndromes were included into this analysis. HLA match between donor and recipient was analyzed at the allele level and classified as 10/10, 9/10 or 8/10. Data were compared to results of 56 MFD-HSCTs. Probability of overall survival (pOS) was given for 3-year and 1-year (as required by JACIE standards) time periods. Results The mean survival for all patients estimated by Kaplan–Meier method was 4.8 years (95%CI=4.1–5.5 years). The 3-year pOS after all UD-HSCT was 0,60±0,05, and with respect to 10/10, 9/10 and 8/10 HLA match: 0,61±0,06; 0,59±0,09 and 0,60±0,22, respectively (ns). In patients with AML, 3-year pOS reached 52%, 60% and 60%, respectively. In patients with ALL, 3-year pOS was 73% and 62% (ns) for 10/10 and 9/10 HLA match, respectively, while for BMF syndromes 86% and 57% (ns), respectively. Conclusion Current data suggest that results of mismatched and matched UD-HSCT in children with acute leukemia might be comparable.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.01.002
       
  • Limfohistiocytoza hemofagocytarna u dzieci
    • Authors: Magdalena Wołowiec; Iwona Malinowska
      Pages: 233 - 241
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Magdalena Wołowiec, Iwona Malinowska
      Hemophagocytic lymphohistiocytosis (HLH) is a heterogenic syndrome characterized by an acute, life-threatening inflammation due to a highly stimulated but ineffective immune response. Depending on the etiology, HLH is divided into primary (genetic) and secondary (acquired) forms. Primary HLH can be divided into familial HLH and HLH associated with other genetic disorders. Secondary HLH usually occurs in the context of a severe infection, rheumatic disease, or malignancy. HLH in children is a rare condition characterized by nonspecific symptoms and poor prognosis. Novel diagnostic tools and therapeutic methods give hope to improve the survival of the patients.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.10.001
       
  • Association of rs1319868, rs1567811 and rs8041224 of IGF1R gene with
           infection among sickle cell anemia Tunisian patients
    • Authors: Mouna Ben Sassi; Leila Chaouch; Miniar Kalai; Imen Moumni; Houyem Ouragini; Imen Darragi; Dorra Chaouachi; Imen Boudrigua; Raouf Hafsia; Salem Abbes
      Pages: 242 - 247
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Mouna Ben Sassi, Leila Chaouch, Miniar Kalai, Imen Moumni, Houyem Ouragini, Imen Darragi, Dorra Chaouachi, Imen Boudrigua, Raouf Hafsia, Salem Abbes
      Background and aim Sickle cell anemia (SCA) is characterized by variable patterns of clinical expression. Polymorphisms linked to different genes have been associated with specific complications of the disease. Herein, we focused on the study of the association of 4 polymorphisms of Insulin like Growth Factor 1 receptor (IGF1R) gene with infections, which are the major cause of death in SCA. Material and methods This study involved 116 sickle cell patients among whom 58 SS have the same confirmed infectious phenotype. Allele-Specific PCR was performed for the study of rs1319868, whereas the PCR/sequencing method was carried out for rs1567811, rs2872060 and rs8041224. Results The results showed that rs1319868 and rs1567811 were associated with a decreased risk of infection among SS patients (p =0.038, RR=0.54; p =0.044, RR=0.56, respectively). Interestingly, the combination of different genotypes showed the association of the genotype GT of rs1319868 and the genotype CC of rs8041224 with further decreased infection risk in SCA (p =0.028, RR=0.04). Conclusion These significant associations of IGF1R SNPs with infection suggest that this gene could play an important role in the immune function in SCA.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.10.004
       
  • Analiza mutacji talasemii alfa u chorych diagnozowanych w Instytucie
           Hematologii i Transfuzjologii
    • Authors: Edyta Klimczak-Jajor; Joanna Skulimowska; Paweł Turowski; Hanna Pyl; Małgorzata Uhrynowska; Katarzyna Guz; Ewa Mendek-Czajkowska; Anna Ejduk; Izabella Kopeć; Marzena Dębska; Ewa Brojer
      Pages: 248 - 253
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Edyta Klimczak-Jajor, Joanna Skulimowska, Paweł Turowski, Hanna Pyl, Małgorzata Uhrynowska, Katarzyna Guz, Ewa Mendek-Czajkowska, Anna Ejduk, Izabella Kopeć, Marzena Dębska, Ewa Brojer
      Background Alpha-thalassemia is genetically transmitted hemolytic anemia resulting from disturbance of the globins chain synthesis. Alpha-thalassemia is caused most frequently by deletions and less commonly by nondeletional defects. Aim To introduce the molecular methods for routine identifications of alpha-thalassemia mutations and to study the characteristics of these mutations in Poland. Methods Blood sample of 155 patients with normal or reduced HbA2 values was obtained for blood counting. All samples underwent gap-PCR to screen for the seven common α-thal deletions and MLPA analysis. The DNA of 21 patients in which deletions were not detected has been directly sequenced. Results We detected mutations in the alpha-globin gene in 72 of 155 patients studied. 55 out of 72 cases showed most common thalassemia deletions, as the following: a single gene deletion (α3.7 and α4.2) and both genes deletion (FIL, SEA, MED I, and α20.5). Owing to the use of MLPA technique, we found nontypical deletions in another 12 patients and multiplication of the alpha-globin genes in further 4 cases. We also identified a patient with a point mutation HBA2: c.300 + 2T>A by DNA sequencing. Conclusions Molecular analysis of the alpha-globin cluster is required for a correct diagnosis in patients with normal or reduced level of HbA2. The results of the study show that due to the progressive migration of the population and globalization, thalassemia must be included in the differential diagnosis of anemia in Poland.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.10.002
       
  • Transfusion-associated graft-vs-host disease – A case report
    • Authors: Jina Bhattacharyya; Nilom Khound; Bhaskar Jyoti Kakati; Mrinal Bhattacharyya; Sangit Dutta; Aishwarya Raj
      Pages: 254 - 257
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Jina Bhattacharyya, Nilom Khound, Bhaskar Jyoti Kakati, Mrinal Bhattacharyya, Sangit Dutta, Aishwarya Raj
      Transfusion-associated graft-vs-host disease (TAGVHD) is a rare complication of blood transfusion. Unlike GVHD associated with hematopoietic stem cell transplantation TA-GVHD involves the patient's bone marrow and leads to bone marrow aplasia. We report a case of TA-GVHD in a 45-year-old post-hysterectomy patient after packed red blood cell transfusion from a sibling donor. The patient had fever, maculopapular rashes all over the body, elevated transaminases, and hyperglycemia after a week of the blood transfusion. Severe pancytopenia and bone marrow aplasia followed and she succumbed to her disease after 3 weeks of onset.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.10.005
       
  • Precursor B-lymphoblastic lymphoma mimicking: An acute subdural hematoma
    • Authors: Ant Uzay; Siret Ratip; Ilhan Elmaci; Metin Ozdemirli
      Pages: 258 - 262
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Ant Uzay, Siret Ratip, Ilhan Elmaci, Metin Ozdemirli
      Objective and importance We present the first case of a precursor acute subdural B-lymphoblastic lymphoma mimicking an acute subdural hematoma. Clinical presentation A 19 year old male presented with an acute onset of headache, nausea and vomiting. CT scan showed crescentic right-sided, frontoparietal subdural mass isointense with cortex and showing homogeneous enhancement after gadolinium. Intervention The patient underwent a craniotomy and a gray subdural tumor with invasion of both dura and brain was observed. The invaded dura was resected and duraplasty performed. Histopathologically, the tumor was composed of small round cells infiltrating soft tissue. In some areas of the tumor, cells were arranged in a linear, “Indian file” fashion between collagen bundles. Their nuclei were generally uniform, round to ovoid in shape, small to medium in size, and featured delicate chromatin. Accompanying cytoplasm was scant. Necrosis was absent. On immunohistochemical analysis, the tumor cells were positive for CD79a, TdT, CD10 and CD34. Conclusion Subdural lymphoma can present as a neurosurgical emergency, and lymphoma should be considered as a rare but possible diagnosis before operation.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.10.003
       
  • Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki
           limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL
    • Authors: Tadeusz Robak; Iwona Hus; Krzysztof Giannopoulos; Jerzy Błoński; Krzysztof Jamroziak; Jacek Roliński; Piotr Smolewski; Dariusz Wołowiec
      Pages: 169 - 183
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Tadeusz Robak, Iwona Hus, Krzysztof Giannopoulos, Jerzy Błoński, Krzysztof Jamroziak, Jacek Roliński, Piotr Smolewski, Dariusz Wołowiec
      The management of patients with chronic lymphocytic leukaemia (CLL) is currently undergoing improvements, particularly because of novel therapies. Purine analogs based immuno-chemotherapy, especially fludarabine combined with cyclophosphamide and rituximab (FCR), is still the current standard of care for first line therapy in younger, fit patients. However, its use in older, co-morbid patients is limited, particularly due to high toxicity. In fit patients older than 65 years or/and with previous infections bendamustine and rituximab (BR) should be considered instead of FCR. Recently, in patients with relevant comorbidities chlorambucil and anti CD20 monoclonal antibodies (rituximab, obinutuzumab or ofatumumab) are recommended as the first-line treatment. In addition, in 2014, two novel agents targeting the B cell receptor (BCR) signaling pathway, ibrutinib and idelalisib, were approved for patients with 17p deletion and/or p53 mutations and in the relapsed situation because of high efficacy and a favorable toxicity. Subsequently, ibrutinib has been approved to treat CLL patients regardless of their treatment history. Thus far it is recommended to treat patients with these agents until progression or unacceptable toxicity. The BCL-2 antagonist venetoclax is another oral drug with very promising preliminary data in patients refractory to immunochemotherapy as well as patients harboring del 17p. In 2014, the PTHiT and PALG-CLL group defined guidelines for the diagnosis, prognosis and treatment of CLL. In this article, we present updated recommendations for therapy of CLL.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.08.003
       
  • Zalecenia dotyczące oceny schorzeń współistniejących u chorych na
           przewlekłą białaczkę szpikową w procesie wyboru inhibitora kinaz
           tyrozynowych
    • Authors: Tomasz Sacha; Sebastian Szmit; Dorota Zozulińska-Ziółkiewicz; Witold Prejzner; Joanna Góra-Tybor
      Pages: 184 - 196
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Tomasz Sacha, Sebastian Szmit, Dorota Zozulińska-Ziółkiewicz, Witold Prejzner, Joanna Góra-Tybor
      Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.06.001
       
  • Stres siateczki śródplazmatycznej i stres oksydacyjny w ostrych
           białaczkach szpikowych
    • Authors: Justyna Chlebowska
      Pages: 197 - 204
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Justyna Chlebowska
      Use of differentiation-inducing agents (all-trans retinoic acid and arsenic trioxide) that degradate fusion PML-RARα receptor have revolutionized management of acute promyelocytic (APL) leukemia in 2008. However, despite significant advances in the treatment of APL, the cure rates of patients suffering with other acute myeloid leukemia (AML) subtypes are still not satisfying. Abnormal reactive oxygen species levels and constitutive expression of ER stress marker proteins are characteristic of AML. AML patients with activated unfolded protein response and increased ER chaperone levels showed suppressed CEBPα protein expression. CEBPα is an essential transcription factor that regulates multiple aspects of myelopoiesis. Understanding how the unfolded protein response trigger down-regulation of CEBPα and lead to differentiation blockage opens new possibilities for the design of anti-AML therapeutic strategies.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.07.001
       
  • Koncentrat płytek krwi napromieniowany czy poddany redukcji biologicznych
           czynników chorobotwórczych – który składnik wybrać w celu
           profilaktyki poprzetoczeniowej choroby
           przeszczep-przeciw-gospodarzowi'
    • Authors: Piotr Olbromski; Piotr Radziwon
      Pages: 205 - 210
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Piotr Olbromski, Piotr Radziwon
      Attributable mortality due to transfusion-associated graft-versus-host disease (TA-GVHD) in contrary to the reaction occurring after transplantations has been estimated to be more than 95%. This type of reaction may occur not only in immunocompromised patients but also in patients without immune deficits. Because there is currently no available treatment for TA-GVHD and very high mortality the goal has been to reduce the likelihood of occurrence in recipients at risk of TA-GVHD. The removal of all lymphocytes from blood components is very difficult and highly impracticable. Much easier way to neutralize lymphocytes presents irreversible injury of their genetic material. It can be achieved by using ionizing irradiation (gamma- or X-ray) or pathogen reduction technologies (PRT). PRT use ultraviolet light with or without photosensitizers. Since PRT cause damage to nucleic acids, they also have potential to inactivate lymphocytes T, making them unable to proliferate, engraft and cause TA-GVHD. Transmission of infections, particularly those not routinely tested in blood components, presents still significant problem in spite of constant improvement of methods applied for donor qualification, blood testing and preparation techniques. PRT have a goal to minimize the risk of transfusion-related pathogen transmission. PRT are equally effective in TA-GVHD prophylaxis as gamma irradiation and according to current guidelines may be applied alternatively. However PRT have advantage over gamma irradiation because they additionally decrease the risk of pathogen transmission via platelet concentrate transfusion and limit proinflammatory cytokine production as well as lymphocyte activation in blood components.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.04.004
       
  • Monocyty z ekspresją Tie-2 u chorych na przewlekłą białaczkę
           limfocytową
    • Authors: Agnieszka Bojarska-Junak; Piotr Grundszok; Małgorzata Waldowska; Justyna Woś; Sylwia Chocholska; Iwona Hus; Wioleta Kowalska; Katarzyna Gęca; Waldemar Tomczak; Jacek Roliński
      Pages: 211 - 218
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Agnieszka Bojarska-Junak, Piotr Grundszok, Małgorzata Waldowska, Justyna Woś, Sylwia Chocholska, Iwona Hus, Wioleta Kowalska, Katarzyna Gęca, Waldemar Tomczak, Jacek Roliński
      Introduction In peripheral blood, monocytes form a heterogeneous population of cells. One particular subset of circulating monocytes is expressing the angiopoietin receptor Tie-2 (Tie2-expressing monocyte; TEM). TEM are characterized by tumor promoting properties. However, the role of TEM in chronic lymphocytic leukemia (CLL) immunopathogenesis remains undefined. Material and Methods Here, we evaluated the monocytes with Tie-2 expression (CD14+Tie-2+) in peripheral blood of CLL patients (n=55) and normal subjects (n=15) by flow cytometry. We investigated possible associations between TEM and poor prognostic factors such as CD38 or ZAP-70 expression, Rai stage and unfavorable cytogenetic abnormalities. Moreover, we investigated the association of TEM percentage with CD14++CD16+ monocytes and Treg percentages. Results We found that CLL patients had a higher percentage of CD14+Tie-2+ monocytes compared to normal controls. The percentage of TEM was positively associated with ZAP-70 expression as well as with unfavourable cytogenetic changes: del(17p) and/or del(11q). The frequency of TEM increased with the disease stage. We showed no correlation between the percentage of TEM and CD38 expression. The percentage of TEM at diagnosis was associated with white blood cell count as well as with the percentages of CD19+CD5+ lymphocytes and Tregs. The majority of CD14+Tie-2+ cells belonged to the intermediate monocytes subset (CD14++CD16+) while fewer of them were among the classical (CD14++CD16−) or non-classical monocyte (CD14+CD16++) subsets. TEM and CD14++CD16+ monocytes have a proangiogenic activity, suppress T-cell activation and promote Treg expansion. The results suggest that monitoring of TEM number and function may provide useful information in determining disease activity.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.08.001
       
  • Retrospektywna analiza skuteczności nilotynibu i dazatynibu w drugiej
           linii terapii przewlekłej białaczki szpikowej w polskich ośrodkach
           hematologicznych [Acta Haematologica Polonica 2016; 47(3): 219–225]
    • Authors: Anna Stępień; Krzysztof Jamroziak; Tomasz Sacha; Dorota Link-Lenczowska; Izabela Florek; Witold Prejzner; Zofia Specht-Szwoch; Małgorzata Całbecka; Marcin Rymko; Marek Dudziński; Paulina Wieszczy; Krzysztof Warzocha; Janina Góra-Tybor
      Pages: 219 - 225
      Abstract: Publication date: October–December 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 4
      Author(s): Anna Stępień, Krzysztof Jamroziak, Tomasz Sacha, Dorota Link-Lenczowska, Izabela Florek, Witold Prejzner, Zofia Specht-Szwoch, Małgorzata Całbecka, Marcin Rymko, Marek Dudziński, Paulina Wieszczy, Krzysztof Warzocha, Joanna Góra-Tybor


      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.08.002
       
  • Retrospektywna analiza skuteczności nilotynibu i dazatynibu w drugiej
           linii terapii przewlekłej białaczki szpikowej w polskich ośrodkach
           hematologicznych
    • Authors: Anna Stępień; Krzysztof Jamroziak; Tomasz Sacha; Dorota Link-Lenczowska; Izabela Florek; Witold Prejzner; Zofia Specht-Szwoch; Małgorzata Całbecka; Marcin Rymko; Marek Dudziński; Paulina Wieszczy; Krzysztof Warzocha; Janina Góra-Tybor
      Pages: 219 - 225
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Anna Stępień, Krzysztof Jamroziak, Tomasz Sacha, Dorota Link-Lenczowska, Izabela Florek, Witold Prejzner, Zofia Specht-Szwoch, Małgorzata Całbecka, Marcin Rymko, Marek Dudziński, Paulina Wieszczy, Krzysztof Warzocha, Janina Góra-Tybor
      Until now, there has been no randomized study directly comparing the activity of second-generation BCR-ABL tyrosine kinase inhibitors (TKI-2G) nilotinib and dasatinib in chronic myeloid leukemia (CML). The aim of our study was to retrospectively analyze efficacy of nilotinib and dasatinib in the real life setting of CML with resistance or intolerance of imatinib. Of 108 included patients treated in polish hematology centers, 75 received dasatinib and 33 patients received nilotinib. Rates of complete cytogenetic response (CCyR) did not differ between the two groups of patients. After six months of therapy, CCyR was achieved in 34.7% of patients treated with dasatinib and 38.7% treated with nilotinib (p=0.86), while after 12 months, the CCyR rates were 60.0% and 77.0% in dasatinib and nilotinib groups, respectively (p=0.11). Moreover, we have not observed any significant difference in the probability of progression-free survival (p=0.89) or overall survival (p=0.99) between patients treated with these two TKI-2G. In conclusion, the results of our analysis indicate that nilotinib and dasatinib have comparable and satisfactory efficacy in the treatment of CML patients refractory or intolerant to imatinib. Our findings support current strategy of choice of IKT-2G according to drug toxicity profile and risk of specific adverse events in an individual patient.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.08.002
       
  • Effective pain reduction during bone marrow biopsy and aspiration –
           Technique over experience
    • Authors: Emil Jaddini; Nikolaj Hjortholm; Emilian Snarski
      Pages: 226 - 231
      Abstract: Publication date: July–September 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 3
      Author(s): Emil Jaddini, Nikolaj Hjortholm, Emilian Snarski
      Background: Bone marrow biopsy and aspiration (BMBA) is a diagnostic procedure within the field of internal medicine. The intensity of the pain felt by the patients often goes unrecognized by the medical staff. No extant studies have addressed pain intensity experienced during each particular step of a BMBA. Objectives: The aim was to analyze the pain intensity and explore the extent to which the technique applied by the doctor performing the biopsy influences the pain level. Methods: A survey comprising 17 questions was created and it addressed characteristics of the patients, previous experience and pain intensity on each step of the procedure. Results: 125 patients were enrolled into the study. Age (p =0.009), gender (p =0.02), pain during previous biopsies (p <0.0001) and adequate information (p =0.04) were shown to have significant impact on the pain intensity levels. There was a significant difference in the pain levels on different steps of the procedure perceived by the patients, when comparing the doctors with similar experience performing BMBA (p =0.01 to p <0.0001 depending on the step of the procedure). Conclusions: The differences in the pain scores between the doctors are most likely caused by differences in technique of BMBA. The analysis of the individual technique of the doctors performing the least painful biopsies may give answers needed for educational intervention aimed at pain reduction during BMBA.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.04.003
       
  • Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia
           
    • Authors: Anna Dmoszyńska; Adam Walter-Croneck; Barbara Pieńkowska-Grela; Lidia Usnarska-Zubkiewicz; Jan Walewski; Grzegorz Charliński; Wiesław Wiktor Jędrzejczak; Elżbieta Wiater; Ewa Lech-Marańda; Krzysztof Jamroziak; Agnieszka Druzd-Sitek; Dominik Dytfeld; Mieczysław Komarnicki; Tadeusz Robak; Artur Jurczyszyn; Joanna Mańko; Aleksander Skotnicki; Sebastian Giebel; Ryszard Czepko; Janusz Meder; Bogdan Małkowski; Krzysztof Giannopoulos
      Pages: 39 - 85
      Abstract: Publication date: April–June 2016
      Source:Acta Haematologica Polonica, Volume 47, Issue 2
      Author(s): Anna Dmoszyńska, Adam Walter-Croneck, Barbara Pieńkowska-Grela, Lidia Usnarska-Zubkiewicz, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Dominik Dytfeld, Mieczysław Komarnicki, Tadeusz Robak, Artur Jurczyszyn, Joanna Mańko, Aleksander Skotnicki, Sebastian Giebel, Ryszard Czepko, Janusz Meder, Bogdan Małkowski, Krzysztof Giannopoulos
      New drugs introduced in recent years for the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first-line therapy, lenalidomide represents a cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance or treatment till progression. Beside concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described also therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2016.04.010
       
  • Extraneural relapse of medulloblastoma mimicking acute leukemia: A
           diagnostic challenge in adult patient
    • Authors: Monika Joks; Maciej Machaczka; Anna Czyż; Jolanta Parulska; Maciej Majcherek; Jan Bręborowicz; Grzegorz Dworacki; Mieczysław Komarnicki
      Abstract: Publication date: Available online 12 August 2017
      Source:Acta Haematologica Polonica
      Author(s): Monika Joks, Maciej Machaczka, Anna Czyż, Jolanta Parulska, Maciej Majcherek, Jan Bręborowicz, Grzegorz Dworacki, Mieczysław Komarnicki
      Medulloblastoma is the most frequent malignant tumor of the central nervous system (CNS) in children, but it can rarely occur in adults. Extraneural relapse of medulloblastoma occurs very rarely and it is usually associated with dismal prognosis. We present a case of young adult with relapsed medulloblastoma with extraneural metastases in the bone marrow and expression of terminal deoxynucleotidyl transferase (TdT) on the malignant cells mimicking acute leukemia. To the best of our knowledge, this is the first report of medulloblastoma exhibiting expression of the TdT in adult. We would like to emphasize that in cases like this, differential diagnosis of anemia and thrombocytopenia in adults should include a consideration of primary or secondary bone marrow involvement by medulloblastoma or other rare malignancy.

      PubDate: 2017-08-21T19:55:49Z
      DOI: 10.1016/j.achaem.2017.08.002
       
  • Rituximab-associated progressive multifocal leukoencephalopathy after a
           single cycle of R-CHOP for T-cell/histiocyte-rich large B-cell lymphoma
    • Authors: Moa Forssberg; Monika Klimkowska; Maciej Machaczka
      Abstract: Publication date: Available online 12 August 2017
      Source:Acta Haematologica Polonica
      Author(s): Moa Forssberg, Monika Klimkowska, Maciej Machaczka
      Progressive multifocal leukoencephalopathy (PML) is a disease of immunocompromised patients caused by reactivation of the John Cunningham polyomavirus (JCV). A monoclonal anti-CD20 antibody rituximab is widely used as an important part of therapy for B-cell non-Hodgkin lymphomas and various autoimmune diseases. It is not fully explained how rituximab reactivates JCV. In this report, we present the case of a 61-year-old man with T-cell/histiocyte-rich large B-cell lymphoma who was treated with R-CHOP and intrathecal methotrexate. Two weeks after the first R-CHOP course he developed dysarthria, diplopia, and disturbances in motor coordination. Based on CT/MRI results showing 3cm×2cm large hypodense white matter lesion in left cerebellar hemisphere, and detection of JCV in the cerebrospinal fluid (14300viral copies/mL), the patient was diagnosed with PML. Despite treatment attempt with cidofovir and IVIG, the patient's neurological status continued to worsen. He developed progressive motor neuron deficits but retained intact cognitive functions. The patient deceased nearly three months after onset of rituximab treatment. Rituximab is a milestone in treatment of many hematological and autoimmune diseases. Considering how widespread has the use of rituximab become, the overall risk of developing PML is relatively low. Nevertheless, since the end of 1990s several reports were published on PML development in association with usage of rituximab. The authors would like to emphasize that although the total risk of PML occurrence in patients treated with rituximab is low, it is important that physicians administrating rituximab therapy are aware of this serious complication.

      PubDate: 2017-08-21T19:55:49Z
      DOI: 10.1016/j.achaem.2017.08.003
       
  • Część II: Wytyczne postępowania w hemofilii A i B powikłanej
           inhibitorem czynnika VIII i IX (2 wydanie)
    • Authors: Jerzy Windyga; Krzysztof Chojnowski; Anna Klukowska; Magdalena Łętowska; Andrzej Mital; Wojciech Młynarski; Jacek Musiał; Jarosław Peregud-Pogorzelski; Maria Podolak-Dawidziak; Jacek Treliński; Anetta Undas; Tomasz Urasiński; Joanna Zdziarska; Krystyna Zawilska
      Abstract: Publication date: Available online 8 August 2017
      Source:Acta Haematologica Polonica
      Author(s): Jerzy Windyga, Krzysztof Chojnowski, Anna Klukowska, Magdalena Łętowska, Andrzej Mital, Wojciech Młynarski, Jacek Musiał, Jarosław Peregud-Pogorzelski, Maria Podolak-Dawidziak, Jacek Treliński, Anetta Undas, Tomasz Urasiński, Joanna Zdziarska, Krystyna Zawilska
      In this article, the Working Group for Haemostasis of the Polish Society of Haematology and Blood Transfusion updates the principles of diagnosis and treatment of haemophilia A and B complicated by factor VIII or IX inhibitors, which were published for the first time in 2008. In the first part of the Guidelines published in 2016, the management of haemophilia A and B without factor VIII and IX inhibitors was dealt with.

      PubDate: 2017-08-11T12:23:52Z
      DOI: 10.1016/j.achaem.2017.08.001
       
  • Methods for detection of microparticles derived from blood and endothelial
           cells
    • Authors: Małgorzata Gradziuk; Piotr Radziwon
      Abstract: Publication date: Available online 5 August 2017
      Source:Acta Haematologica Polonica
      Author(s): Małgorzata Gradziuk, Piotr Radziwon


      PubDate: 2017-08-11T12:23:52Z
      DOI: 10.1016/j.achaem.2017.03.003
       
  • Zmiany w badaniach kontroli jakości składników krwi w
           Polsce
    • Authors: Lachert
      Abstract: Publication date: Available online 29 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Elżbieta Lachert
      Introduction One of the tasks of blood transfusion centers (BTCs) is the implementation of a quality assurance system that monitors all stages of blood component preparation – from donor qualification to the issue of blood components for clinical use. One element of this system is the quality control of blood components. At least 75% of the units (90% in the case of leukodepleted blood components) should meet the minimum of quality control requirements; otherwise the BTCs are obliged to launch corrective and preventive actions. Among others these actions include monitoring of procedures for sample collection, verification of analytical methods, apparatus, disposable equipment as well as monitoring the whole process of blood component preparation. The aim of the study was to analyze the results of quality control performed in BTCs in the period 1995–2013. Material and methods The analysis was based on quality control protocols from Polish BTCs. Results In the period 1995–1999 the percentage of leukodepleted platelet concentrates which met the quality control criteria was low (from 10% in 1995 to 63.6% in 1996). Quality control protocols from the period 1995 to 2001 (with the exception of 1999) reported a very low percentage of apheresis units meeting quality control criteria. The percentage of pooled platelet concentrates meeting minimum quality control criteria in 2011 and 2012 was estimated at less than 70%. In 2012–2013 a significant decrease in platelet count for apheresis PCs was reported (Tables 1 and 2). Conclusions The implementation of modern techniques/methods of blood component preparation as well as staff training at regular intervals contributed to higher percentage of blood components that meet quality control criteria. The periodical reduction in the number of PCs meeting minimum quality control criteria was most likely due to higher demand for this type of blood component and thus higher frequency of using split apheresis PCs.

      PubDate: 2017-08-01T10:30:42Z
       
  • Aloplasty of an ankylosed knee in a patient with severe haemophilia A
    • Authors: Jerzy Mirosław Jaworski; Adam Zawojski; Joanna Zdziarska; Krzysztof Czernicki; Magdalena Wilk-Frańczuk
      Abstract: Publication date: Available online 29 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Jerzy Mirosław Jaworski, Adam Zawojski, Joanna Zdziarska, Krzysztof Czernicki, Magdalena Wilk-Frańczuk
      The goal of this report is to describe a case of knee arthroplasty in a patient with over a 20 year long history of ankylosis of the left knee joint in the course of severe haemophilia A. Clinical and functional conditions were assessed by means of a Knee Society Score (KSS); pain intensity by Visual Analogue Scale (VAS); and intensity of degeneration of bone forming the joint by means of the Kellgren-Lawrence Scale. ROM of the knee joint before and after the operation was measured. We used hinge prosthesis of S-ROM by De Puy to restore the knee joint. As a result of the operation we got axial alignment of the limb. During two years of clinical follow-up, the patient achieved increasing mobility of the operated knee, full extension, and 80 degrees of active flexion. There were no radiological signs of loosening of the implant. The patients’ functional capabilities improved significantly; and pain occurred only occasionally.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.008
       
  • Zastosowanie cytometrii przepływowej w badaniach
           immunohematologicznych krwinek czerwonych
    • Authors: Jadwiga Fabijańska-Mitek; Anna Stachurska
      Abstract: Publication date: Available online 27 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Jadwiga Fabijańska-Mitek, Anna Stachurska
      Flow cytometry (FC) has been primarily applied to the diagnosis of hematological malignancies, and thereafter, to detection and quantification of CD34+ cells in bone marrow transplants, and granulocytes in neutropenias and paroxysmal nocturnal hemoglobinuria (PNH). In PNH and hereditary spherocytosis, changes in some of the erythrocyte membrane proteins are tested (CD59, CD55, and band 3). The purpose of this paper is to focus on the use of FC in RBC testing. With anti-D, -HbF, and -CA (carbonic anhydrase), we can detect RhD+, HbF+, and CA- fetal RBCs in the maternal RhD-, HbF-, and CA+ blood sample. Obtained results allow to select the appropriate dose of anti-D Ig in the RhD prophylaxis of feto-maternal incompatibility, or to detect the cause of fetal anemia. Expression of antigens and their weak variants, and concentration of specific antibodies, can also be assessed. It is possible to observe changes in selected CD molecules during storage of RBC units. If RBCs for transfusion are unavailable, due to patient's unusual antibody specificity, some of the available RBCs are opsonised, and then phagocytosis with the recipient monocytes is assessed. The microscopic time-consuming and subjective assay is usually used. Stained CD14+ monocytes and CD235a+ erythrocytes are visible on cytograms as well as their interaction. It makes evaluation of phagocytosis easier and objective. Microparticles of RBCs released during storage are also detected. They are 235a+. In differentiation of hemolysis causes, it is important to measure osmotic fragility, and that can be also achieved using FC. Flow cytometry should be applied to immunohematological testing of red blood cells more often than now.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.005
       
  • Nietypowe objawy kliniczne szpiczaka plazmocytowego
    • Authors: Artur Jurczyszyn; Magdalena Olszewska-Szopa
      Abstract: Publication date: Available online 27 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Artur Jurczyszyn, Magdalena Olszewska-Szopa
      Multiple myeloma accounting for 10% of malignancies of haematopoietic system is a heterogenous disease. In the era of individual approach to the patient, we are more and more interested in distinct features and forms of this malignancy. In the article, we described rare MM manifestations with reference to location (central nervous system and skin), M-protein produced by the tumor cells (biclonal and immunoglobulin M), early onset of the disease (young versus old) and pregnancy in MM patients.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.004
       
  • Elevated serum concentrations of β-2-microglobulin are often found at the
           time of diagnosis of hemophagocytic lymphohistiocytosis in adults with
           lymphoid and myeloid malignancies
    • Authors: Egle Sumskiene; Ewa Pawłowicz; Cecilia Kämpe Björkvall; Maciej Machaczka
      Abstract: Publication date: Available online 24 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Egle Sumskiene, Ewa Pawłowicz, Cecilia Kämpe Björkvall, Maciej Machaczka
      Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder of immune regulation. In patients over 60 years of age, HLH associated with hematological malignancies (hM-HLH) is the most prevalent. β-2-Microglobulin (B2M) plays an important role in antigen presentation and immunological regulation. Elevated B2M levels reflect T-cell activation. Objective: The aim of this study was to determine serum B2M concentrations in adults with hM-HLH and to interpret its significance in the context of overall survival (OS). Patients and methods: Serum B2M concentration was determined in 31 adults aged 22–84 years at the time of hM-HLH diagnosis. Lymphoid malignancy was diagnosed in 22 patients and myeloid malignancy in 9 patients. Results: The serum concentration of B2M was elevated in 100% of the examined patients. Mean and median serum B2M concentrations were 5.3 and 4.2mg/L, respectively (range 2–17mg/L). We have not found any significant differences in terms of the studied serum B2M concentrations between patients with T/NK-cell lymphomas, B-cell lymphomas, and myeloid malignancies. The outcome of HLH was poor in vast majority of patients with the median OS for the entire group of 46 days. Conclusions: Elevated serum B2M level is a frequent finding at the time of hM-HLH diagnosis in adults. It seems to be a useful indicator of HLH for its early detection and evaluation afterward, as well as for immediate therapeutic intervention. Further prospective studies answering the question whether serum B2M can be used as a prognostic factor in hM-HLH would be of interest.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.001
       
  • Jak rozpoznawać i leczyć chorobę Gauchera: zarys patofizjologii,
           objawów klinicznych, metod diagnostycznych i leczenia
    • Authors: Egle Sumskiene; Maciej Machaczka
      Abstract: Publication date: Available online 24 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Egle Sumskiene, Maciej Machaczka
      Rare diseases are a diagnostic challenge for modern medicine. Gaucher disease is a rare autosomal recessive lipid storage disorder caused by the deficient activity of the lysosomal enzyme glucocerebrosidase. In the absence of known affected family member, frequent symptoms of Gaucher disease, such as thrombocytopenia or splenomegaly, often lead to hematological diagnostic workup. This review highlights pathophysiology, signs and symptoms, diagnostic and therapeutic principles of Gaucher disease. Difficulties in diagnosis of Gaucher disease depends mainly on its rarity, but there is also the lack of awareness and limited knowledge about this disease. Basic knowledge of Gaucher disease should be familiar to all physicians, including hematologists.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.003
       
  • Ryzyko przeniesienia czynników zakaźnych przez transfuzje w
           Polsce
    • Authors: Piotr Grabarczyk; Aneta Kopacz; Ewa Sulkowska; Aleksandra Kalińska
      Abstract: Publication date: Available online 24 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Piotr Grabarczyk, Aneta Kopacz, Ewa Sulkowska, Aleksandra Kalińska
      Blood transfusion in Poland is the safest in history. High virological level of safety has been achieved mainly by improving not only the qualification of donors and methods used for donor screening, but also applying leukoreduction, pathogen reduction technology and grace period for serum. In this article, we discuss the improvement of the epidemic situation among blood donors for hepatitis B virus (HBV) and hepatitis C virus (HCV) and the increasing trend for HIV. Preliminary results of residual risk calculation for these pathogens are presented. Hepatitis E virus (HEV) and Babesia microti were considered as new factors potentially relevant for the safety of blood transfusion in our country. Due to evidence of West Nile virus (WNV) circulation in the ecosystem in Poland, it is also necessary to monitor the infections with this pathogen. In this article, it was emphasized that the reporting of all possible complications associated with transfusion and meticulous implementation of the look-back procedure play a key role for monitoring the risk of transmission of infectious agents by blood. It is especially important in view of the increasing epidemiological problems associated with emerging infectious agents.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.07.006
       
  • Ekspresja CD10 na minimalnych komórkach resztkowych u dzieci z ostrą
           białaczką limfoblastyczną B-komórkową
    • Authors: Joanna Włodek; Karolina Bukowska-Strakova; Anna Pituch-Noworolska; Walentyna Balwierz; Marta Surman
      Abstract: Publication date: Available online 27 May 2017
      Source:Acta Haematologica Polonica
      Author(s): Joanna Włodek, Karolina Bukowska-Strakova, Anna Pituch-Noworolska, Walentyna Balwierz, Marta Surman
      Background The most common childhood malignancy is B-cell precursor acute leukemia (BCP-ALL). Leukemic cells remaining in the patient's bone marrow during treatment are the major cause of relapse; therefore, minimal residual disease monitoring (MRD) during the induction therapy is predicting factor of treatment outcome. Multicolor flow cytometry (MFC) is the commonly used technique during follow-up of leukemia in bone marrow. Materials and methods MRD was assessed by MFC in 44 patients with BCP-ALL from the Oncology and Hematology Department, Children's University Hospitalin Krakow diagnosed between 2011 and 2013. The level of residual leukemic cells and the quality of antigen expression was assessed on leukemic cell on diagnosis day and 15th day of induction chemotherapy. Six-color panel of monoclonal antibodies was used. To achieve expected sensitivity of the method (10-4), at least 300.000 nucleated cells were collected. Results CD10 expression was changed in residual leukemic cells of most patients on day 15 of treatment, in comparison to day 0. The most significant decrease of CD10 expression occurs in standard risk group. CD10 level is correlated with the level of blasts in day 15, which is the most significant in high-risk group. The patients, in whom the level of CD10 expression increases during treatment, were statistically significantly associated with worse response to therapy. Conclusions The immunophenotypic shifts at day 15 were observed in most patients. Not only are the quantitative MRD results important, but also qualitative changes of immunophenotype of residual leukemic cells might bring additional clinical information.

      PubDate: 2017-08-01T10:30:42Z
      DOI: 10.1016/j.achaem.2017.04.002
       
  • Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem
           plazmocytowym
    • Authors: Krzysztof Giannopoulos; Wiesław Wiktor Jędrzejczak; Krzysztof Jamroziak; Dominik Dytfeld; Tadeusz Robak; Andrzej Hellmann
      Abstract: Publication date: Available online 23 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Krzysztof Giannopoulos, Wiesław Wiktor Jędrzejczak, Krzysztof Jamroziak, Dominik Dytfeld, Tadeusz Robak, Andrzej Hellmann
      Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.

      PubDate: 2017-07-24T08:27:56Z
      DOI: 10.1016/j.achaem.2017.07.002
       
  • Efficacy and safety of bosutinib in the second and third line of treatment
           in chronic myeloid leukemia
    • Authors: Bogdan Ochrem; Tomasz Sacha
      Abstract: Publication date: Available online 10 July 2017
      Source:Acta Haematologica Polonica
      Author(s): Bogdan Ochrem, Tomasz Sacha


      PubDate: 2017-07-14T06:15:44Z
      DOI: 10.1016/j.achaem.2017.03.002
       
  • Możliwości leczenia indukcyjnego chorych na szpiczaka plazmocytowego
           kwalifikujących się do chemioterapii wysokodawkowanej wspomaganej
           autologiczną transplantacją komórek krwiotwórczych a aktualne
           zalecenia Polskiej Grupy Szpiczakowej
    • Authors: Agnieszka Druzd-Sitek; Jan Walewski
      Abstract: Publication date: Available online 15 June 2017
      Source:Acta Haematologica Polonica
      Author(s): Agnieszka Druzd-Sitek, Jan Walewski
      Despite significant progress in the treatment of multiple myeloma, it still remains an incurable disease. The introduction of new drugs has contributed to the increased overall survival of patients diagnosed with multiple myeloma and significantly improved their quality of life. Proteasome inhibitors, immunomodulators and monoclonal antibodies are often used in combination with chemotherapeutic agents. Despite the indisputable role of the new drugs for the treatment of myeloma, high-dose chemotherapy with autologous stem cell transplantation is still the method of choice in a group of younger patients without significant comorbidities. Induction treatment in myeloma patients eligible for autologous stem cell transplantation is particularly important, because the results of the first-line therapy impact further outcome of patients. The quality of the response to first-line treatment determines the progression-free survival. The choice of bortezomib, thalidomide, dexamethasone regimen as induction therapy, recommended by the Polish Myeloma Group, is in line with the recommendations of international experts. The results of the randomized clinical trials have demonstrated that the triple therapy, based on proteasom inhibitors, immunomodulators and steroids, is more effective than regimens involving two drugs only (proteasom inhibitors and steroids or immunomodulators and steroids). Sometimes, due to the clinical situation of the patient and/or unusual features of the disease, it is necessary to individualize induction therapy. The following article provides an overview of different induction regimens for myeloma patients in Poland and suggestions for modifications in justified cases.

      PubDate: 2017-06-17T21:18:01Z
      DOI: 10.1016/j.achaem.2017.06.001
       
  • Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia
           
    • Authors: Anna Dmoszyńska; Lidia Usnarska-Zubkiewicz; Jan Walewski; Ewa Lech-Marańda; Adam Walter-Croneck; Barbara Pieńkowska-Grela; Grzegorz Charliński; Wiesław Wiktor Jędrzejczak; Bogdan Małkowski; Krzysztof Jamroziak; Agnieszka Druzd-Sitek; Dominik Dytfeld; Mieczysław Komarnicki; Tadeusz Robak; Artur Jurczyszyn; Joanna Mańko; Aleksander Skotnicki; Sebastian Giebel; Elżbieta Wiater; Ryszard Czepko; Janusz Meder; Krzysztof Giannopoulos
      Abstract: Publication date: Available online 7 June 2017
      Source:Acta Haematologica Polonica
      Author(s): Anna Dmoszyńska, Lidia Usnarska-Zubkiewicz, Jan Walewski, Ewa Lech-Marańda, Adam Walter-Croneck, Barbara Pieńkowska-Grela, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Bogdan Małkowski, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Dominik Dytfeld, Mieczysław Komarnicki, Tadeusz Robak, Artur Jurczyszyn, Joanna Mańko, Aleksander Skotnicki, Sebastian Giebel, Elżbieta Wiater, Ryszard Czepko, Janusz Meder, Krzysztof Giannopoulos
      New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first line therapy, lenalidomide represents the cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance treatment till progression. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described therapeutic recommendation also for Waldenström macroglobulinemia and other plasmacytic dyscrasias.

      PubDate: 2017-06-12T19:08:31Z
      DOI: 10.1016/j.achaem.2017.05.003
       
  • Metastasis of solid tumors into bone marrow – Single center
           experience
    • Authors: Anna Kołda; Grzegorz Helbig; Anna Kopińska; Ryszard Wichary; Jacek Pająk; Sławomira Kyrcz-Krzemień
      Abstract: Publication date: Available online 31 May 2017
      Source:Acta Haematologica Polonica
      Author(s): Anna Kołda, Grzegorz Helbig, Anna Kopińska, Ryszard Wichary, Jacek Pająk, Sławomira Kyrcz-Krzemień
      Introduction: Metastases of solid tumors to the bone marrow are rarely reported. Clinical manifestation and laboratory findings remain uncharacteristic and lead to misdiagnosis. Detection of bone marrow metastases may have an impact on therapeutic decisions and is usually associated with poor prognosis. Aim: To characterize clinical picture and hematological findings in patients with bone marrow metastasis. Material and methods: We retrospectively reviewed medical records of patients with bone marrow metastases who were primary misdiagnosed with hematological malignancies. Results: Ten patients at median age of 51 years at diagnosis were included. There were following findings on admission: duopenia (n =7), pancytopenia (n =1), anemia (n =1) and skeletal lytic lesions (n =1). The diagnosis of prior cancer was reported in 3 patients and included multiple myeloma, breast cancer and oligoastrocytoma. Clinical manifestations were hepatomegaly (n =4), lymphadenopathy (n =4), skin pallor (n =3), cachexia (n =2) and hemorrhagic diathesis (n =2). Imaging studies revealed diffuse bone lesions (n =5), pulmonary infiltrates (n =2) and liver masses (n =2). Leukoerythroblastosis was demonstrated in 4 cases. Bone marrow aspirate detected the presence of abnormal cell population in 4 patients. In all studied patients a final diagnosis was established by immunohistochemistry of bone marrow biopsy. The following malignancies were detected: prostate adenocarcinoma (n =2), anaplastic microcellular carcinoma of unknown origin (n =2), adenocarcinoma of unknown origin (n =2), Ewing's sarcoma (n =1), breast cancer (n =1), clarocellular renal cancer (n =1) and neuroendocrine tumor (n =1). Nine out of the 10 metastatic patients died shortly after chemotherapy. Conclusions: Unexplained hematological abnormalities should arise the suspicion of bone marrow metastases.

      PubDate: 2017-06-02T15:41:08Z
      DOI: 10.1016/j.achaem.2017.05.001
       
  • Primary Hodgkin lymphoma of the nasopharynx: Case report
    • Authors: Justyna Grela-Kowalik; Dariusz Zatoński; Tomasz Zatoński
      Abstract: Publication date: Available online 25 May 2017
      Source:Acta Haematologica Polonica
      Author(s): Justyna Grela-Kowalik, Dariusz Zatoński, Tomasz Zatoński
      Primary extranodal location of Hodgkin lymphoma is uncommon. We present a case of a 43-year old man with isolated Hodgkin disease localized in the nasopharynx who presented with a complaint of bilateral nasal congestion. Primary location of Hodgkin lymphoma (HL) in the non-lymphoid tissue is very uncommon and the primary isolated involvement of the nasopharynx has been described in 35 cases in the worldwide literature.

      PubDate: 2017-05-28T10:26:37Z
      DOI: 10.1016/j.achaem.2017.04.001
       
  • Haemate P − zastosowanie w profilaktyce i leczeniu krwawień w chorobie
           von Willebranda oraz indukcji immunotolerancji w hemofilii A powikłanej
           inhibitorem
    • Authors: Andrzej Mital
      Abstract: Publication date: Available online 23 May 2017
      Source:Acta Haematologica Polonica
      Author(s): Andrzej Mital
      Haemate P is a plasma-derived concentrate used in the treatment of von Willebrand disease and haemophilia A. In comparison with other concentrates, this product is characterised by a high content of high-molecular-weight multimers. The ratio of von Willebrand factor (vWF:RCo) to factor VIII (FVIII) is 2.4:1. Haemate P is used with a high efficacy and safety when desmopressin (DDAVP) is ineffective or contraindicated, in all forms of von Willebrand disease (vWD), in the treatment of bleeding, in preparation for surgery and in prophylaxis in some patients, especially those with type 3 of the disease. The favourable vWF:RCo/FVIII ratio prevents accumulation of FVIII and related thromboembolic complications. Haemate P has been considered a gold standard in the treatment of von Willebrand disease for many years. This concentrate is used also in haemophilia A replacement therapy. One of the complications of haemophilia A treatment is the development of anti-FVIII antibodies called an inhibitor. The objective of the treatment of those patients is the elimination of the inhibitor, possibly through inducing immune tolerance (IT). The efficacy of Haemate P in immune tolerance induction both in the first and consecutive lines of treatment has been demonstrated by many reports. Replacement of highly-purified and recombinant FVIII concentrates in the case of failure to induce IT to concentrates with a high vWF:RCo content may be a beneficial treatment option in another attempt of inducing IT.

      PubDate: 2017-05-24T09:58:24Z
      DOI: 10.1016/j.achaem.2017.05.002
       
  • Metody oznaczania hemoglobiny płodowej
    • Authors: Elżbieta Górska; Anna Lemańska; Katarzyna Popko
      Abstract: Publication date: Available online 4 May 2017
      Source:Acta Haematologica Polonica
      Author(s): Elżbieta Górska, Anna Lemańska, Katarzyna Popko
      The identification of the new form of hemoglobin in fetus red blood cells (HbF), different from adult hemoglobin (HbA), was made over one hundred years ago. Since this time, various methods of fetal hemoglobin measurement have been designed. Most of them are based on the different biochemical characteristics of HbF. Fetal hemoglobin's affinity for oxygen is substantially greater than that of adult hemoglobin. The first techniques for the determination of fetal hemoglobin were based on its resistance to denaturation by alkaline solutions. Currently, the measurement of hemoglobin F is an important part of diagnosis of sickle cell disease, thalassemia, hereditary persistence of fetal hemoglobin, and fetomaternal hemorrhage. Amongst the most commonly used and clinically important methods, high-performance liquid chromatography, capillary electrophoresis, isoelectric focusing, capillary isoelectric focusing, Kleihauer–Betke test, and flow cytometry should be listed.

      PubDate: 2017-05-08T13:23:29Z
      DOI: 10.1016/j.achaem.2016.12.001
       
  • Visceral varicella-zoster virus (VZV) infection as an underestimated
           differential diagnosis of acute abdomen in a patient after allogeneic
           hematopoietic stem cell transplantation
    • Authors: Julia Radoń-Proskura; Ninela Irga-Jaworska; Anna Malinowska; Jan Maciej Zaucha
      Abstract: Publication date: Available online 15 March 2017
      Source:Acta Haematologica Polonica
      Author(s): Julia Radoń-Proskura, Ninela Irga-Jaworska, Anna Malinowska, Jan Maciej Zaucha
      We report a case of 18-year-old male patient who 5.5 months after allogeneic hematopoietic stem cell transplant (HSCT) developed severe abdominal pain not responding to high dose of opioids. The pain was accompanied by gradually increasing activity of liver enzymes and bilirubin concentration. The patient had a history of acute GVHD and was on steroid taper. Importantly, he was also temporarily off standard acyclovir prophylaxis. Provisional diagnosis of acute cholecystitis was made, however, cholecystectomy did not improve patient's condition. Clinical picture of severe abdominal pain without clear surgical cause, resistant to high doses of opiates with increasing activity of liver enzymes was highly suspicious of visceral varicella zoster virus (VZV) reactivation. Immediate introduction of intravenous acyclovir led to full recovery and complete resolution of abdominal pain. We conclude that reactivation of latent VZV with absent or delayed occurrence of characteristic skin vesicles may still pose a diagnostic challenge resulting in delay of the proper diagnosis and start of life saving antiviral treatment. Severe intractable pain in HSCT recipients with increasing activity of liver enzymes should evoke high index of suspicion of the possible disseminated VZV and impose start of empirical treatment with high dose acyclovir.

      PubDate: 2017-03-16T04:40:07Z
      DOI: 10.1016/j.achaem.2017.02.001
       
  • Osoczowe stężenie cytruliny w klinicznej ocenie toksyczności jelitowej
           u chorych na nowotwory złośliwe poddanych chemioterapii wysokodawkowej
           [Acta Haematologica Polonica 2015; 46(S): 190–191]
    • Authors: J. Barzał; P. Rzepecki; M. Jaworska; E. Anuszewska
      Abstract: Publication date: Available online 11 March 2017
      Source:Acta Haematologica Polonica
      Author(s): J. Barzał, P. Rzepecki, M. Jaworska, E. Anuszewska


      PubDate: 2017-03-16T04:40:07Z
      DOI: 10.1016/j.achaem.2017.03.001
       
  • Szczepienia ochronne u chorych dorosłych po przeszczepieniu komórek
           krwiotwórczych – zalecenia sekcji do spraw zakażeń PALG
    • Authors: Agnieszka Piekarska; Sebastian Giebel; Grzegorz Władysław Basak; Jarosław Dybko; Kazimierz Hałaburda; Iwona Hus; Ewa Karakulska-Prystupiuk; Beata Jakubas; Patrycja Mensah-Glanowska; Piotr Rzepecki; Agnieszka Wierzbowska; Lidia Gil
      Abstract: Publication date: Available online 16 February 2017
      Source:Acta Haematologica Polonica
      Author(s): Agnieszka Piekarska, Sebastian Giebel, Grzegorz Władysław Basak, Jarosław Dybko, Kazimierz Hałaburda, Iwona Hus, Ewa Karakulska-Prystupiuk, Beata Jakubas, Patrycja Mensah-Glanowska, Piotr Rzepecki, Agnieszka Wierzbowska, Lidia Gil
      Infections are the most serious complications in patients undergoing hematopoietic cell transplantation (HCT). Vaccinations occur to be undeniably one of the most important prophylactic strategies and are routinely recommended in the post-transplantation period. Their use reduces the incidence of infections and infection-related mortality. In this paper, we present the current guidelines for active immunization after HCT for the Polish patient population as worked out by the Polish Adult Leukemia Group (PALG). The guidelines include the recommended vaccines, the optional vaccines and vaccination with live pathogens. The management in specific situations such as graft versus host disease and for HCT recipients travelling to exotic countries is clarified. We also present the proposal for organization of the vaccination program in transplant centers. The improvement in realization of the vaccination protocol is one of the key aspects of post-transplantation care in Poland.

      PubDate: 2017-02-23T16:30:29Z
      DOI: 10.1016/j.achaem.2017.01.003
       
  • Alloimmunologiczna małopłytkowość noworodków
    • Authors: Irmina Nowak; Weronika Kubiak-Prałat; Marcin Minta; Marta Szymankiewicz; Janusz Gadzinowski; Dawid Szpecht
      Abstract: Publication date: Available online 16 February 2017
      Source:Acta Haematologica Polonica
      Author(s): Irmina Nowak, Weronika Kubiak-Prałat, Marcin Minta, Marta Szymankiewicz, Janusz Gadzinowski, Dawid Szpecht
      Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is defined as a platelet count <150,000/μL due to reaction between maternal antibodies and antigens located on thrombocytes of the fetus/neonate. Such a kind of pathology occurs when a mother does not possess specific human platelet antigens (HPA), which are inherited as an infant from the father. HPA-1a is an antigen that most often causes FNAIT in the Caucasian race. Frequency of FNAIT has been estimated as 1:350–1:5000. In the pathogenesis of FNAIT, the mother organism is immunized and produces alloantibodies from which IgG pass through the placenta, enter fetal circulatory system and cause platelet destruction. It usually takes place at the end of the second trimester. FNAIT can occur in the first pregnancy; nonetheless, it is more probable and connected with higher severity in subsequent gestations. It is caused by the fact that immunization usually takes place during the first labour, which enables production of alloantibodies in the next pregnancies. Nevertheless, other ways of immunization are also possible, which ensures that FNAIT cases in the first pregnancy are not casuistic and occur more often than RhD hemolytic disease of the newborn. Thrombocytopenia leads to coagulation disorders, and consequently to bleedings. FNAIT can be manifested not only by some petechiae on the skin, but also by severe hemorrhages in the body cavities and gastrointestinal tract or by intracranial hemorrhages (ICH). In case the symptoms are presented by an infant, platelet transfusions are performed, and IVIG (intravenous immunoglobulin) therapy is administered.

      PubDate: 2017-02-23T16:30:29Z
      DOI: 10.1016/j.achaem.2017.01.004
       
  • Wyniki stosowania nowych metod rehabilitacji u pacjentów z
           artropatią hemofilową
    • Authors: Janusz Zawilski; Adrian Dudek; Przemysław Lisiński
      Abstract: Publication date: Available online 19 January 2017
      Source:Acta Haematologica Polonica
      Author(s): Janusz Zawilski, Adrian Dudek, Przemysław Lisiński
      Advanced arthropathy mainly of the knee, hip or ankle joint occurs even in young adults with haemophilia. It has been proved that physical training increases isometric muscular strength and proprioceptive performance in haemophilia patients. The aim of this study was to present the new methods of physiotherapy process and their effect in patients with haemophilic arthropathy. Five subjects, aged from 32 to 42 years, with severe haemophilia A or B attended physiotherapy in a outpatient ambulatory setting over a 3-month period. The following treatment modalities were performed: walking on AlterG anti-gravity treadmill, deep penetrating electromagnetic stimulation (Salus Talent), manual physical therapy, mobilization and manipulation techniques, active muscle-strengthening exercises, post isometric relaxation (PIR) muscle energy techniques, as well as exercises for improvement of coordination, postural equilibrium and proprioception exercises using sensorimotor discs. The HJHS (Haemophilia Joint Health Score) has been used to assess the effectiveness of the treatment, VAS scale (Visual Analog Scale) to assess level of pain, TUG test (Timed Up and Go) to assess mobility as well as dynamic and static balance. Strength of the muscles acting on the joints improved, swelling of joints diminished and the level of pain decreased. An improvement of the dynamic and static balance was found as well. The range of motion did not change. Physiotherapy process did not provoke bleeding episodes in patients with haemophilic arthropathy included to the study.

      PubDate: 2017-01-19T20:04:21Z
      DOI: 10.1016/j.achaem.2016.11.005
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.196.74.153
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016